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Objectives: The present study aimed at investigating the impact of mandatory 
clinical clerkship courses on fifth year pharmacy students’ attitudes and perceived 
barriers toward providing pharmaceutical care (PC). MethOds: A cross-sectional 
survey was conducted among 5th year pharmacy students undertaking manda-
tory clinical clerkship in the University of Gondar, Ethiopia. A pharmaceutical care 
attitudes survey (PCAS) questionnaire was used to assess the attitude (14 items), 
commonly identified drug-related problem/s (1 item) during clerkships, and per-
ceived barriers (12 items) toward the provision of PC. Statistical analysis was con-
ducted on the retrieved data. Results: Among the total of 69 clerkship students, 
65 participated and completed the survey (94.2% response rate). Overall, 74.45% 
of participants had positive attitude toward PC provision. Almost all respondents 
agreed that the primary responsibility of pharmacists in the healthcare setting was 
to prevent and solve medication-related problems (98.5%), practice of PC was valu-
able (89.3%), and the PC movement will improve patient health (95.4%), respectively. 
Unnecessary drug therapy (43%), drug-drug interactions (33%), and non-adherence 
to medications (33%) were the most common drug-related problems identified in 
wards. Highly perceived barriers for PC provision included lack of a workplace for 
counseling in the pharmacy (75.4%), a poor image of pharmacist’s role in wards 
(67.7%), and inadequate technology in the pharmacy (64.6%). Lack of access to a 
patient’s medical record in the pharmacy had significant association (P< 0.05) with 
PC practice, performance of PC during clerkship and provision of PC as clinical 
pharmacists cOnclusiOns: Students attending the new clinical pharmacy pro-
gram in Ethiopia have a good attitude toward pharmaceutical care. However, the 
barriers to pharmaceutical care need to be addressed by integrating PC provision 
with pharmacy practice.
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Objectives: Aim of this research was to investigate ideal attribution with revealing 
the relevance between pharmacy attribution and patients’ outcomes. MethOds: A 
self-completion questionnaire from composed of two forms of “Pharmacy attribute” 
and “Patients attribute” was delivered to 3321 pharmacies across Japan which agreed 
to join in January 2013. Pharmacy attribute: a number of pharmacist, prescription/
day, home-visiting patients/ month, cooperated medical facilities. Patients attribute: 
adverse drug event, change in prescription, change in adherence, finding of unused 
drugs, and change in the amount of unused drugs. We grouped by 2 indexes (a num-
ber of prescription/day/pharmacist as ‘work load’ and cooperated medical facilities 
as ‘positivity to cooperate’) to 4 groups. (Used SPSS ver.21) Results: Among 1,890 
community pharmacies data (collecting rate: 56.9%), we extracted answers to all 
the question items about community pharmacy attribute necessary for grouping. 
The 1,327 community pharmacies data was collected as the target (the number of 
patient data: for 4,947) for the analysis. The data of 1327 pharmacies showed the 
middle of attribution showed 20 prescriptions filled /day/pharmacist (work load) 
and 1 medical facility cooperated. The group of ‘Prescriptions≦20 and Cooperated 
facility> 1’ and the groups of ‘Prescriptions> 20 and Cooperated facility> 1’ 
changed in prescription(p< 0.003), changed in adherence(p< 0.001), find of unused 
drugs(p< 0.001), and decreased the amount of unused drugs (p< 0.001) more than 
others. There is no significant differences in adverse drug event. cOnclusiOns: 
It was suggested that there was relationship between pharmacy attribution (work 
load/ positivity to cooperate) and patient’s outcomes on healthcare service of home-
visiting.
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Objectives: This study was conducted to assess the knowledge, attitude and 
practice of community pharmacists (CPs) towards ADR reporting and monitor-
ing. MethOds: A prospective cross sectional study was conducted at selected 
community pharmacies. Pharmacists at selected pharmacies were administered 
a questionnaire by research pharmacist and two weeks’ time was given to each 
pharmacist to complete the survey. Questionnaire was designed with various 
elements which can evaluate knowledge, attitude and practice of pharmacists 
towards ADR reporting. Results: A total of 256 community pharmacists were 
approached at selected community pharmacies per study criteria and were admin-
istered a questionnaire. Of 256, only 56 CPs (21.8%) responded to the survey. Of 56 
respondents, 37.5% were able to define ADR correctly, whereas 35.7% of pharmacists 
believed ADRs solely as allergic response. Only 46% of pharmacists could correctly 
identify potential risk factors responsible to cause ADRs and 57% of pharmacists 
were aware of the consequences of ADRs. Almost 93% of respondents admit that 
safety reporting is an important responsibility of pharmacist however, surprisingly 
almost 73.2% pharmacists were not aware of existing pharmacovigilance program 
in the country. As per 78.5% respondents ADR reporting in the community phar-
macies lead to additional workload. Looking at willingness to report, almost 50% 
of pharmacists expect incentives to get involve in the safety reporting and other 
50% feels it as professional responsibilities which do not require incentives. Among 
respondents only 20% of them had ever reported ADR to nearer national safety 
reporting centres. However, majority of CPs are interested to contribute for ADR 
reporting if appropriate training is provided. cOnclusiOns: Majority community 
pharmacists do not possess required knowledge on ADR reporting, its importance 
and national safety reporting program. There is a strong need to implement edu-
cational and regulatory interventions periodically to improve the understanding of 
safety reporting among CPs.
“baseline” year served as control data. Results: There were 1500 intervention and 
286 control participants with mean age (sd) 72.75 (7.82) and 73.39 years (7.31), and 
past year fall rates of 22.8% and 21.8%, respectively. Males comprised 23.1% of the 
intervention group and 24.8% of the control group. Majority were of Chinese eth-
nicity (86.7% of intervention and 81.1% of controls). Improvements from baseline 
to 52 weeks were significantly better (p< 0.05) for intervention participants than 
controls for the Six Minute Walk Test, Step Test, Falls Efficacy Score and Life Space 
Assessment; Safer Score was significantly better on follow-up for the intervention 
group. There was no significant difference in the Berg Balance, Timed-Up-And-Go, 
Chair Rise and EQ-5d. Intervention participants had significantly fewer falls in the 
third quarter of follow-up (95%CI of the difference= 0.00,0.10). Multivariate results 
revealed that the intervention group had significantly fewer falls for the entire 
follow-up year (Odds Ratio = 0.75, 95%CI = 0.58,0.97). cOnclusiOns: Results sug-
gest that the program improves physical performance and reduces the incidence of 
falls in the elderly. Residents may be empowered to take responsibility for prevent-
ing falls in their own community.
PHP155
systematiC Review of fda BReaKtHRougH tHeRaPy designated 
PRoduCts
Aggarwal S1, Kumar S2, Topaloglu H1
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, 
USA
Objectives: In 2012, the United States Food and Drug Administration (FDA) created 
a new expedited pathway of “Breakthrough Therapy Designation” (BTD) to enable 
an early approval of therapies which have shown substantial activity in early trials. 
The objective of this study was to assess the comparative effectiveness and pric-
ing of drugs with BTD. MethOds: The data for the number of granted BTDs was 
obtained from FDA.gov. The data for publically disclosed BTDs was obtained from 
sponsor’s press releases. For all products, the information for their mechanism 
of action, type of molecule, trial design, clinical efficacy and safety, and pricing 
and time to approval (for approved products) were obtained from peer-reviewed 
publications, conference abstracts, FDA and sponsor websites. Results: Since the 
establishment of the BTD pathway, 55 products have been granted breakthrough 
therapy designations (2012-2015), of which, 42 have been publically disclosed by the 
manufacturers and 6 have been approved by the FDA. In terms of indications, 43% 
are for cancer, 18% are for genetic diseases and 14% are for Hepatitis C Genotype 
1. The median time to approval for these three drug was ~5 years, significantly 
shorter than the 2012 median time to approval for priority review applications 
(6 years). The price premium was 30-50%, compared to other drugs in the same 
category. The six approved BTDs show 20-30% higher response rates than other 
products in the same category. The other products in the pipeline with established 
comparators show 36%-136% improvement in efficacy (based on active controls or 
previous trials). For approximately half of the products, comparative efficacy can-
not be determined because of no previous evidence for a product with efficacy in 
the targeted indications. cOnclusiOns: BTD is a promising pathway to shorten 
development time and provides early access, however, the high price could pose 
challenges for payers and patients.
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Objectives: To understand how comparative effectiveness research (CER) is being 
used by US managed care plans and pharmaceutical benefit managers (PBMs) to 
control the growth of healthcare costs and ensure appropriate utilization of products 
by pharmacy and therapeutics (P&T) committees. MethOds: Managed care (MC) 
medical and pharmacy directors (MDs+PDs) completed an online interactive survey. 
Topics included: advisor and plan information and current/future coverage of CER. 
The use of CER and evidence-based medicine (EBM) was evaulated using a 5-point 
likert scale (5= completely agreeing;1= completely disagreeing). Results: Fifty-four 
percent of respondents were MDs, the remainder mostly pharmacists. Most worked 
for a health plan (83.6%) and 39.6% of the plans were local; 35.4% national; and 25.0% 
regional. Public (Medicare and Medicaid) and private (Commercial) plans were rep-
resented. When asked to select the area emerging CER is expected to affect: value of 
care (29.8%), optimization/improvement of clinical guidelines (27.7%), appropriate-
ness of care (14.9%), pharmaceutical research and development (6.4%), medical and 
pharmacy benefit management (17.0%), and 4.3% uncertain. When asked about their 
agreement in “progress in obtaining usable information on CER of therapies” the 
results were slightly negative with 42.5% disagreeing (34%= somewhat,8.5%= com-
pletely), 38.3% agreeing (4.3%= completely,34%= somewhat), and 19.1% neutral. When 
asked if they expect their plan to use CER regularly in formulary decision making by 
2015, more than half (53.2%,14.9%= completely,38.3%= somewhat) agreed, 27.7% disa-
greed (23.4%= somewhat,4.3%= completely), and 19.1% were neutral. When asked 
to assess how “MC commonly using EBM today in coverage decision making” the 
results were more favorable with 79.2% agreeing (27.1%= completely,52.1%= some-
what); 14.6% neutral and 6.3% disagreeing (6.3%= somewhat,0%= completely). The 
most desired change to their plan’s/PBM’s P&T process was for increased use of CER; 
and a move toward contractual risk-sharing. cOnclusiOns: Formulary decision 
making in P&T committees is making progress in the use of comparative effective-
ness research. Results suggest that the acceptance of evidence-based medicine is 
valuable even if not comparative.
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